论文部分内容阅读
目的:探究不同手术方式联合新辅助化疗治疗乳腺癌患者的临床疗效。方法:选择2012年1月~2014年1月我院收治的80例乳腺癌患者为研究对象。综合考虑患者自主意愿、身体条件、经济状况,将80例乳腺癌患者分为A组(23例)和B组(57例)。两组患者均给予EC(表柔比星+环磷酰胺)方案新辅助化疗,在此基础上A组接受保乳术,B组接受改良根治术。比较两组患者临床疗效、乳房美容效果、生活质量、心理状态。结果:A组患者的住院时间、拔管时间均显著短于B组(P<0.05),术中出血量、HAMA、HRSD评分、术后并发症的发生率明显低于B组(P<0.05),乳房美容效果明显优于B组(P<0.05),QLQ-BR23评分显著高于B组(P<0.05)。两组患者随访期间的2年生存率、复发率比较差异均无统计学意义(P>0.05)。结论:保乳术联合表柔比星新辅助化疗治疗乳腺癌的临床效果显著,可减少术后并发症,提高乳房美观度和患者的生活质量。
Objective: To investigate the clinical effects of different surgical methods combined with neoadjuvant chemotherapy in patients with breast cancer. Methods: 80 cases of breast cancer admitted to our hospital from January 2012 to January 2014 were selected as the research object. Totally 80 patients with breast cancer were divided into group A (23 cases) and group B (57 cases), considering the patient’s own wishes, physical condition and economic status. Both groups were given neoadjuvant chemotherapy with EC (epirubicin + cyclophosphamide) regimen, on the basis of which group A received lactation and group B received modified radical mastectomy. The clinical efficacy, breast cosmetic results, quality of life and psychological status of the two groups were compared. Results: The length of hospital stay and extubation in group A were significantly shorter than those in group B (P <0.05). The incidences of intraoperative bleeding, HAMA, HRSD and postoperative complications were significantly lower than those in group B (P <0.05) ), Breast cosmetic effect was significantly better than the B group (P <0.05), QLQ-BR23 score was significantly higher than the B group (P <0.05). There was no significant difference in the 2-year survival rates and recurrence rates between the two groups during follow-up (P> 0.05). Conclusion: The effect of breast-conserving surgery combined with epirubicin neoadjuvant chemotherapy in the treatment of breast cancer is significant, which can reduce the postoperative complications, improve the esthetic appearance and the quality of life of the patients.